Luspatercept treatment affects immune-regulatory subsets in patients with MDS with ring sideroblasts
• Luspatercept in low-risk MDS-RS patients reduces high suppressive Tregs and mMDSC. • Low mMDSC levels and active CTL response may represent predictive markers for Luspatercept response in MDS-RS patients.
Authors
- Annamaria Vincenzi (ORCID: https://orcid.org/0009-0003-5975-9388)
- Antonio Vassallo (ORCID: https://orcid.org/0000-0001-7937-3309)
- G Cerciello
- Alessandra Picardi (ORCID: https://orcid.org/0000-0002-0136-7686)
- Giuseppe Terrazzano (ORCID: https://orcid.org/0000-0003-3556-6891)
- Mara Memoli (ORCID: https://orcid.org/0000-0002-1922-6048)
- Giuseppina Ruggiero (ORCID: https://orcid.org/0000-0002-8975-6001)
- Fabrizio Pane (ORCID: https://orcid.org/0000-0003-2563-4125)
- Flavia Carriero (ORCID: https://orcid.org/0009-0005-0625-353X)
- Francesco Grimaldi (ORCID: https://orcid.org/0000-0003-2286-5091)
- Giulia Scalia (ORCID: https://orcid.org/0000-0002-2721-0134)
- Valentina Rubino (ORCID: https://orcid.org/0000-0002-5646-2795)
- Maria Di Perna (ORCID: https://orcid.org/0000-0003-2977-0634)
- Stefania Leone
Institutions
- University of Rome Tor Vergata (IT)
- University of Sannio (IT)
- University of Basilicata (IT)
- Ospedale Antonio Cardarelli (IT)
- Azienda Ospedaliera G.Rummo (IT)
- CTO Andrea Alesini (IT)
- Federico II University Hospital (IT)
- CEINGE Biotecnologie Avanzate Franco Salvatore (Italy) (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Blood Neoplasia
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.bneo.2025.100170
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00